Scott D Seiwert

Summary

Publications

  1. ncbi Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)
    Scott D Seiwert
    InterMune, Inc, 3280 Bayshore Blvd, Brisbane, CA 94005, USA
    Antimicrob Agents Chemother 52:4432-41. 2008
  2. ncbi HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives
    Guangyi Wang
    Discovery Research, InterMune, Inc, Brisbane, CA 94005, USA
    Bioorg Med Chem Lett 19:4476-9. 2009
  3. ncbi HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives
    Guangyi Wang
    Discovery Research, InterMune, Inc, Brisbane, CA 94005, USA
    Bioorg Med Chem Lett 19:4480-3. 2009
  4. ncbi Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution
    Sharlene R Lim
    InterMune, Inc, Brisbane, California, USA
    Antimicrob Agents Chemother 56:271-9. 2012
  5. ncbi Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior
    Ravi Rajagopalan
    InterMune Inc, 3280 Bayshore Boulevard, Brisbane, California 94005, USA
    Biochemistry 48:2559-68. 2009
  6. ncbi Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein
    Shawn Misialek
    InterMune, Brisbane, CA 94005, USA
    Anal Biochem 394:138-40. 2009
  7. ncbi HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives
    Guangyi Wang
    Discovery Research, InterMune, Inc, Brisbane, CA 94005, USA
    Bioorg Med Chem Lett 19:4484-7. 2009
  8. ncbi Monitoring protein modification with allosteric ribozymes
    Narendra K Vaish
    Sirna Therapeutics, Inc, 2950 Wilderness Place, Boulder, CO 80301, USA
    Methods 32:428-36. 2004
  9. ncbi Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection
    Caralee J Schaefer
    InterMune, Inc, Brisbane, California 94005, USA
    Antimicrob Agents Chemother 55:3125-32. 2011
  10. ncbi Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections
    Tony Wang
    InterMune Inc, Brisbane, CA 94005, USA
    J Interferon Cytokine Res 26:473-83. 2006

Collaborators

Detail Information

Publications11

  1. ncbi Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227)
    Scott D Seiwert
    InterMune, Inc, 3280 Bayshore Blvd, Brisbane, CA 94005, USA
    Antimicrob Agents Chemother 52:4432-41. 2008
    ..These preclinical characteristics compare favorably to those of other inhibitors of NS3/4A in clinical development and therefore support the clinical investigation of ITMN-191 for the treatment of chronic hepatitis C...
  2. ncbi HCV NS5B polymerase inhibitors 1: Synthesis and in vitro activity of 2-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives
    Guangyi Wang
    Discovery Research, InterMune, Inc, Brisbane, CA 94005, USA
    Bioorg Med Chem Lett 19:4476-9. 2009
    ..2-(1,1-Dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-1-hydroxynaphthalene derivatives as potential anti-HCV drugs targeting NS5B polymerase have been investigated. Their synthesis, HCV NS5B polymerase inhibition and replicon activity are discussed...
  3. ncbi HCV NS5B polymerase inhibitors 2: Synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives
    Guangyi Wang
    Discovery Research, InterMune, Inc, Brisbane, CA 94005, USA
    Bioorg Med Chem Lett 19:4480-3. 2009
    ..1,1-Dioxo-2H-[1,2,4]benzothiadiazin-3-yl) azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives have been investigated as potential anti-HCV drugs. Their synthesis, HCV NS5B polymerase inhibition, and replicon activity are discussed...
  4. ncbi Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution
    Sharlene R Lim
    InterMune, Inc, Brisbane, California, USA
    Antimicrob Agents Chemother 56:271-9. 2012
    ..These data indicate the ascendant importance of R155K for viral escape during danoprevir treatment and may have implications for the clinical use of this agent...
  5. ncbi Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior
    Ravi Rajagopalan
    InterMune Inc, 3280 Bayshore Boulevard, Brisbane, California 94005, USA
    Biochemistry 48:2559-68. 2009
    ..Slow dissociation is not observed with closely related macrocyclic inhibitors of NS3, suggesting that members of this class may display distinct binding kinetics...
  6. ncbi Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein
    Shawn Misialek
    InterMune, Brisbane, CA 94005, USA
    Anal Biochem 394:138-40. 2009
    ..These conditions enable a particularly sensitive protease assay that uses picomolar concentrations of NS3...
  7. ncbi HCV NS5B polymerase inhibitors 3: Synthesis and in vitro activity of 3-(1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)-4-hydroxy-2H-quinolizin-2-one derivatives
    Guangyi Wang
    Discovery Research, InterMune, Inc, Brisbane, CA 94005, USA
    Bioorg Med Chem Lett 19:4484-7. 2009
    ..Their synthesis, HCV NS5B polymerase inhibition, and replicon activity are discussed...
  8. ncbi Monitoring protein modification with allosteric ribozymes
    Narendra K Vaish
    Sirna Therapeutics, Inc, 2950 Wilderness Place, Boulder, CO 80301, USA
    Methods 32:428-36. 2004
    ..These significant differences from antibodies allow the pre-programmed development of conformation-state-specific protein detection reagents that can be used to investigate the activation-state of signal transduction components...
  9. ncbi Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection
    Caralee J Schaefer
    InterMune, Inc, Brisbane, California 94005, USA
    Antimicrob Agents Chemother 55:3125-32. 2011
    ....
  10. ncbi Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections
    Tony Wang
    InterMune Inc, Brisbane, CA 94005, USA
    J Interferon Cytokine Res 26:473-83. 2006
    ..These results suggest that addition of IFN-gamma1b to HCV treatment regimens may provide unique benefits...
  11. ncbi Zeptomole detection of a viral nucleic acid using a target-activated ribozyme
    Narendra K Vaish
    Sirna Therapeutics, Inc, Boulder, Colorado 80301, USA
    RNA 9:1058-72. 2003
    ..6 x 10(6)-fold greater than that previously demonstrated by oligonucleotide-activated ribozymes, and one that is sufficient for molecular diagnostic applications...